Interconnected pathways representing the human body

Unlocking the Mystery of ME/CFS: Can Routine Lab Tests Offer a New Path to Diagnosis?

Avery Sinclair in Health & Wellness August 2025 • 4 min read.

"A groundbreaking study suggests that specific clinical laboratory parameters could provide an objective way to diagnose Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, paving the way for earlier interventions and personalized treatment."

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, chronic, and often debilitating condition that affects millions worldwide. Characterized by profound fatigue, cognitive dysfunction, sleep abnormalities, and a range of other symptoms, ME/CFS can significantly impact a person's ability to perform daily activities and maintain a good quality of life.

One of the biggest challenges in managing ME/CFS is the lack of objective diagnostic markers. Currently, diagnosis relies heavily on clinical evaluation and the exclusion of other potential causes, making it a time-consuming and often frustrating process for both patients and healthcare providers. This diagnostic uncertainty not only delays access to appropriate care but also contributes to the dismissal of ME/CFS as a 'real' illness.

But what if there was a way to diagnose ME/CFS with greater accuracy and speed? A recent study published in the Journal of Translational Medicine offers a promising step forward, suggesting that specific clinical laboratory parameters could serve as objective biomarkers for the disease. This article delves into the findings of this study, exploring the potential implications for ME/CFS diagnosis, treatment, and future research.

Decoding ME/CFS: The Promise of Four Clinical Parameters

Interconnected pathways representing the human body

Researchers investigated four clinical parameters to determine if they could help in diagnosing ME/CFS. The study was a retrospective look at 140 ME/CFS cases and 140 healthy controls, focusing on the following:

The investigative approach involved utilizing logistic regression and classification and regression tree analysis to find correlations and patterns within the data. These methods allowed researchers to identify which parameters, alone or in combination, could most accurately differentiate between ME/CFS patients and healthy individuals.

Soluble CD14 (sCD14): A marker of immune activation and bacterial translocation, often elevated in gastrointestinal issues.
Prostaglandin E2 (PGE2): A lipid compound involved in inflammation and immune regulation, with links to premenstrual symptoms commonly reported by women with ME/CFS.
Interleukin-8 (IL-8): A chemokine that attracts immune cells to sites of inflammation and infection, potentially reflecting the body's response to underlying triggers.
CD57+/CD3- NK Cells: Natural killer cells expressing the CD57 marker, which are linked to immune senescence and chronic infections.

After analyzing the data, the researchers found correlations between the four clinical parameters. The best model incorporated serum levels of sCD14, PGE2, and interleukin 8. The statistical analysis revealed significant p-values, indicating a strong association between these parameters and the presence of ME/CFS.

A New Dawn for ME/CFS Diagnosis?

The study's findings suggest that sCD14, PGE2, and IL-8 may serve as valuable markers in diagnosing ME/CFS and potentially offer new insights into the disease's underlying mechanisms. While further research is needed to validate these findings and explore their clinical utility, this study represents a significant step forward in the quest for objective diagnostic tools for ME/CFS. With continued investigation, these parameters could pave the way for earlier diagnosis, personalized treatment approaches, and improved outcomes for individuals living with this challenging condition.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1186/s12967-018-1696-z, Alternate LINK

Title: Evaluation Of Four Clinical Laboratory Parameters For The Diagnosis Of Myalgic Encephalomyelitis

Subject: General Biochemistry, Genetics and Molecular Biology

Journal: Journal of Translational Medicine

Publisher: Springer Science and Business Media LLC

Authors: Kenny L. De Meirleir, Tatjana Mijatovic, Krishnamurthy Subramanian, Karen A. Schlauch, Vincent C. Lombardi

Published: 2018-11-21

Everything You Need To Know

What is Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and why is diagnosis challenging?

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, chronic illness characterized by profound fatigue, cognitive dysfunction, sleep abnormalities, and other symptoms. Diagnosis is challenging because it relies on subjective criteria and the exclusion of other potential causes. This often leads to delayed diagnosis and access to appropriate care, as well as the potential dismissal of the illness.

What specific clinical laboratory parameters are highlighted in the study for ME/CFS diagnosis?

The study focused on four clinical parameters: Soluble CD14 (sCD14), Prostaglandin E2 (PGE2), Interleukin-8 (IL-8), and CD57+/CD3- NK Cells. These parameters were chosen for their potential links to immune activation, inflammation, and immune senescence, all of which are hypothesized to play a role in ME/CFS.

How can Soluble CD14 (sCD14), Prostaglandin E2 (PGE2), and Interleukin-8 (IL-8) potentially help in diagnosing ME/CFS?

The research suggests that sCD14, PGE2, and IL-8 may serve as valuable markers in diagnosing ME/CFS. The study found correlations between these parameters and the presence of ME/CFS. sCD14 is a marker of immune activation and bacterial translocation, PGE2 is involved in inflammation and immune regulation, and IL-8 attracts immune cells to sites of inflammation. Analyzing these parameters together could offer new insights into the disease's underlying mechanisms and lead to earlier and more accurate diagnoses.

Can you explain the role of CD57+/CD3- NK Cells and its implications for ME/CFS?

CD57+/CD3- NK Cells, natural killer cells expressing the CD57 marker, are linked to immune senescence and chronic infections. While the study included CD57+/CD3- NK Cells, the most effective model for ME/CFS diagnosis did not incorporate this parameter. The presence and function of NK cells are essential to the immune system's ability to fight off infections and cancer. In some studies, reduced numbers or altered function of these cells in ME/CFS patients have been observed, suggesting that immune dysfunction may be a contributing factor.

What are the potential implications of this study for ME/CFS patients?

The study's findings offer a promising path toward earlier diagnosis and personalized treatment approaches for individuals with ME/CFS. If validated through further research, the use of sCD14, PGE2, and IL-8 as diagnostic markers could lead to quicker and more accurate diagnoses. This could reduce diagnostic delays and provide access to appropriate care, which could improve outcomes for those living with this challenging condition. Further research will be required to explore the clinical utility and mechanisms behind these parameters.